- Home
- PLX vs MASS Comparison
PLX vs MASS Comparison
Compare PLX & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | MASS |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.0M | 224.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLX | MASS |
|---|---|---|
| Price | $2.97 | $6.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | $12.00 |
| AVG Volume (30 Days) | ★ 1.6M | 387.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.29 | N/A |
| Revenue Next Year | $16.65 | $19.55 |
| P/E Ratio | $43.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $1.92 |
| 52 Week High | $3.10 | $9.34 |
Technical Indicators
Market Signals| Indicator | PLX | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 72.63 | 57.84 |
| Support Level | $2.81 | $6.23 |
| Resistance Level | $3.03 | $6.95 |
| Average True Range (ATR) | 0.17 | 0.38 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 93.00 | 76.40 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.